Summary
Global Markets Direct’s, ‘Essential Thrombocythemia - Pipeline Review, H1 2016’, provides an overview of the Essential Thrombocythemia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Essential Thrombocythemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Essential Thrombocythemia and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia
- The report reviews pipeline therapeutics for Essential Thrombocythemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Essential Thrombocythemia therapeutics and enlists all their major and minor projects
- The report assesses Essential Thrombocythemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Essential Thrombocythemia
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Essential Thrombocythemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Essential Thrombocythemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
ANP Technologies, Inc.
Aop Orphan Pharmaceuticals AG
F. Hoffmann-La Roche Ltd.
Galena Biopharma, Inc.
Gilead Sciences, Inc.
Incyte Corporation
Italfarmaco S.p.A.
MEI Pharma, Inc.
Novartis AG
PharmaEssentia Corporation
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Essential Thrombocythemia Overview 7
Therapeutics Development 8
Pipeline Products for Essential Thrombocythemia - Overview 8
Essential Thrombocythemia - Therapeutics under Development by Companies 9
Essential Thrombocythemia - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Essential Thrombocythemia - Products under Development by Companies 13
Essential Thrombocythemia - Companies Involved in Therapeutics Development 14
ANP Technologies, Inc. 14
Aop Orphan Pharmaceuticals AG 15
F. Hoffmann-La Roche Ltd. 16
Galena Biopharma, Inc. 17
Gilead Sciences, Inc. 18
Incyte Corporation 19
Italfarmaco S.p.A. 20
MEI Pharma, Inc. 21
Novartis AG 22
PharmaEssentia Corporation 23
Essential Thrombocythemia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
anagrelide hydrochloride CR - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
anagrelide hydrochloride PR - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Drug to Inhibit Ribonucleotide Reductase for Polycythemia Vera and Essential Thrombocythemia - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
givinostat - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
momelotinib dihydrochloride - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
peginterferon alfa-2a - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pracinostat - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ropeginterferon alfa-2b - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ruxolitinib phosphate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
sonidegib phosphate - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
vismodegib - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Essential Thrombocythemia - Recent Pipeline Updates 61
Essential Thrombocythemia - Dormant Projects 84
Essential Thrombocythemia - Discontinued Products 85
Essential Thrombocythemia - Product Development Milestones 86
Featured News & Press Releases 86
Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial 86
Feb 13, 2013: Novartis's Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance 86
May 31, 2011: YM BioSciences Announces Orphan Drug Designation For JAK1/JAK2 Inhibitor CYT387 In Europe 87
Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting 88
May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis 89
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91
List of Tables
Number of Products under Development for Essential Thrombocythemia, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Essential Thrombocythemia - Pipeline by ANP Technologies, Inc., H1 2016 14
Essential Thrombocythemia - Pipeline by Aop Orphan Pharmaceuticals AG, H1 2016 15
Essential Thrombocythemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 16
Essential Thrombocythemia - Pipeline by Galena Biopharma, Inc., H1 2016 17
Essential Thrombocythemia - Pipeline by Gilead Sciences, Inc., H1 2016 18
Essential Thrombocythemia - Pipeline by Incyte Corporation, H1 2016 19
Essential Thrombocythemia - Pipeline by Italfarmaco S.p.A., H1 2016 20
Essential Thrombocythemia - Pipeline by MEI Pharma, Inc., H1 2016 21
Essential Thrombocythemia - Pipeline by Novartis AG, H1 2016 22
Essential Thrombocythemia - Pipeline by PharmaEssentia Corporation, H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Essential Thrombocythemia Therapeutics - Recent Pipeline Updates, H1 2016 61
Essential Thrombocythemia - Dormant Projects, H1 2016 84
Essential Thrombocythemia - Discontinued Products, H1 2016 85
List of Figures
Number of Products under Development for Essential Thrombocythemia, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Top 10 Targets, H1 2016 25
Number of Products by Stage and Top 10 Targets, H1 2016 25
Number of Products by Top 10 Mechanism of Actions, H1 2016 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 27
Number of Products by Routes of Administration, H1 2016 29
Number of Products by Stage and Routes of Administration, H1 2016 29
Number of Products by Molecule Types, H1 2016 31
Number of Products by Stage and Molecule Types, H1 2016 31
